Literature DB >> 21724122

Magnetic resonance spectroscopic imaging of benign prostatic tissue: findings at 3.0 T compared to 1.5 T-initial experience.

Munish Chitkara1, Antonio Westphalen, John Kurhanewicz, Aliya Qayyum, Liina Poder, Galen Reed, Fergus V Coakley.   

Abstract

In a retrospective study of 71 voxels of benign peripheral zone tissue from 3 men who underwent endorectal magnetic resonance (MR) spectroscopic imaging of the prostate at both 1.5 and 3 T, 21 voxels that appeared more malignant at 3 T to either of two readers demonstrated significantly higher levels of choline and polyamines at 3 T compared to 1.5 T using a Wilcoxon ranked-sum test; awareness of this selective amplification of these metabolic signals at high field strength may help avoid overdiagnosis of prostate cancer.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724122      PMCID: PMC3721318          DOI: 10.1016/j.clinimag.2010.07.005

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  19 in total

1.  Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging.

Authors:  A A Schricker; J M Pauly; J Kurhanewicz; M G Swanson; D B Vigneron
Journal:  Magn Reson Med       Date:  2001-12       Impact factor: 4.668

2.  Echo-time independent signal modulations using PRESS sequences: a new approach to spectral editing of strongly coupled AB spin systems.

Authors:  G Gambarota; M van der Graaf; D Klomp; R V Mulkern; A Heerschap
Journal:  J Magn Reson       Date:  2005-10-05       Impact factor: 2.229

Review 3.  Abdominal magnetic resonance imaging at 3.0 T: problem or a promise for the future?

Authors:  Shahid M Hussain; Piotr A Wielopolski; Diego R Martin
Journal:  Top Magn Reson Imaging       Date:  2005-07

Review 4.  Body MR imaging at 3.0 T: understanding the opportunities and challenges.

Authors:  Mara M Barth; Martin P Smith; Ivan Pedrosa; Robert E Lenkinski; Neil M Rofsky
Journal:  Radiographics       Date:  2007 Sep-Oct       Impact factor: 5.333

5.  Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy.

Authors:  Patrick Weybright; Pia C Sundgren; Pavel Maly; Diana Gomez Hassan; Bin Nan; Suzan Rohrer; Larry Junck
Journal:  AJR Am J Roentgenol       Date:  2005-12       Impact factor: 3.959

6.  Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.

Authors:  Mark G Swanson; Andrew S Zektzer; Z Laura Tabatabai; Jeffry Simko; Samson Jarso; Kayvan R Keshari; Lars Schmitt; Peter R Carroll; Katsuto Shinohara; Daniel B Vigneron; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2006-06       Impact factor: 4.668

7.  Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T.

Authors:  Charles H Cunningham; Daniel B Vigneron; Malgorzata Marjanska; Albert P Chen; Duan Xu; Ralph E Hurd; John Kurhanewicz; Michael Garwood; John M Pauly
Journal:  Magn Reson Med       Date:  2005-05       Impact factor: 4.668

8.  Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Chaya Moskowitz; Nicole Ishill; Oguz Akin; Kentaro Kuroiwa; Jessica Spector; Mahesh Kumar; Victor E Reuter; Jason A Koutcher; Kristen L Zakian
Journal:  Radiology       Date:  2007-09-21       Impact factor: 11.105

9.  Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

Authors:  Claudia Testa; Riccardo Schiavina; Raffaele Lodi; Eugenio Salizzoni; Barbara Corti; Mohsen Farsad; John Kurhanewicz; Fabio Manferrari; Eugenio Brunocilla; Caterina Tonon; Nino Monetti; Paolo Castellucci; Stefano Fanti; Manuela Coe; Walter F Grigioni; Giuseppe Martorana; Romeo Canini; Bruno Barbiroli
Journal:  Radiology       Date:  2007-07-24       Impact factor: 11.105

10.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury.

Authors:  Qing-Shi Zeng; Chuan-Fu Li; Kai Zhang; Hong Liu; Xiao-Shui Kang; Jun-Hui Zhen
Journal:  J Neurooncol       Date:  2007-02-14       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.